Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - Checkpoint Therapeutics, Inc. | v471795_ex32-2.htm |
| EX-31.2 - EXHIBIT 31.2 - Checkpoint Therapeutics, Inc. | v471795_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - Checkpoint Therapeutics, Inc. | v471795_ex31-1.htm |
| EX-10.2 - EXHIBIT 10.2 - Checkpoint Therapeutics, Inc. | v471795_ex10-2.htm |
| EX-10.1 - EXHIBIT 10.1 - Checkpoint Therapeutics, Inc. | v471795_ex10-1.htm |
| 10-Q - FORM 10-Q - Checkpoint Therapeutics, Inc. | v471795_10q.htm |
Exhibit 32.1
Certification of
Principal Executive Officer
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
I, James F. Oliviero, Chief Executive Officer of Checkpoint Therapeutics, Inc. (the “Company”), in compliance with Section 906 of the Sarbanes-Oxley Act of 2002, hereby certify that, to the best of my knowledge, the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2017 (the “Report”) filed with the Securities and Exchange Commission:
| • | Fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| • | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| /s/ James F. Oliviero | |
| James F. Oliviero | |
| President and Chief Executive Officer | |
| (Principal Executive Officer) | |
| August 9, 2017 |